Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Trial of CAIV-T (FluMist) in Children 6 to <60 Months
2017-000848-17Phase 2
- Sponsor
- MedImmune
- Start
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of live attenuated influenza vaccine in influenza, sponsored by MedImmune. Primary endpoint: Proportion of subjects who shed vaccine virus.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2017-000848-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000848-17.